In today’s briefing:
- Celltrion: Meaningful Increase in Cash and Stock Dividends
- 3 D Matrix Ltd (7777 JP): 1H FY04/25 flash update
- CellSource (4880 JP): Full-year FY10/24 flash update
- Cybin, Inc. – First Dosing of Meticulously Planned CYB003 Phase 3 Program Imminent
Celltrion: Meaningful Increase in Cash and Stock Dividends
- Celltrion Inc (068270 KS) announced meaningful increase in dividends (including both cash and stock dividends).
- Celltrion will pay out stock dividend of 0.05 for shareholders as of record in 2024, this will be 150% higher than the average stock dividend in the past three years.
- Celltrion will also pay out cash DPS of 750 won for shareholders as of record in 2024, which is more than double the average DPS in the past three years.
3 D Matrix Ltd (7777 JP): 1H FY04/25 flash update
- Operating revenue increased by 78.3% YoY to JPY3.3bn, driven by sales of TDM-621 across multiple regions.
- Operating loss narrowed to JPY532mn, with a recurring loss of JPY798mn and a net loss of JPY806mn.
- US sales grew 151.4% YoY, achieving profitability; Europe and Japan also reported significant YoY sales growth.
CellSource (4880 JP): Full-year FY10/24 flash update
- Revenue for FY10/24 was JPY4.4bn, a 3.4% YoY decrease, with operating profit down 89.4% YoY to JPY129mn.
- FY10/25 forecasts include revenue of JPY4.5bn (+3.4% YoY) and operating profit of JPY370mn (+186.5% YoY).
- Contract processing services revenue declined 12.8% YoY in FY10/24, with orders decreasing by 13.9% YoY.
Cybin, Inc. – First Dosing of Meticulously Planned CYB003 Phase 3 Program Imminent
- Addressing skeptics of CYB003’s durability data. As impressive as CYB003’s Phase 2 12-month data are, not everyone fully embraces them because of the small population size (n=7) from which they were generated.
- While this may logically be a fair question, Inamdar addressed this question by stating that not all data are created equal, with some data more impactful than others.
- Even with small numbers, you can have highly impactful data, and CYB003’s data were highly impactful clinically with a 100% response rate, a 70%-plus remission rate, and a mean 23-point MADRS change from baseline versus the two to three-point change that is typically considered by experts to be clinically significant outcomes for depression.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
